Effect of Cadmium Chloride on the Histological Structure of Lung in Adult Male Mice with and without Parsley Oil

This study is to detect the toxic effect of cadmium chloride on the histological structure of the lung and the effect of parsley oil to amilorate these changes In this experiement 40 adult male mice were divided into four groups. Goup A (control group) in this group animals were injected with the normal saline intraperitoneally single daily dose for 30 days. Group B injected intrapertioneally with cadmium chloride single daily dose 3.5 mg/kg body weight for 30 days. Group C injected intraperetonially with cadmium chloride in a dose of 3.5 mg/kg body weight. Intragastric tube was put to recieve parsley oil in a dose of 0.5 ml/kg body weight prior to cadmium injection. The two drugs were given for 30 days. Group D recieved 0.5 ml/kg body weight by intragastric tube of parsley oil for 30 days. At the end of this experiement, the animals were sacrified the lungs were collected from all groups and prepared for light microscopical examination. Histological changes were detected in cadmium chloride treated group in comparison with the control group including congestion, inflammatory cell infiltration, interstial pneumonia (decreased alveolar space), thickening of interalveolar septum and damge to the alveolar cells. All these changes were eliminated by giving parsley oil.

Comparison The Effect of Single Daily Dose With 48 Hours Interval of Amikacin With Meropenem in Treatment With Urinary Tract Infection With E. Coli: A Clinical Trial Study

Objective: Urinary tract infection is among the most prevalent infections in humans, and E. coli is the most frequent pathogen causing this disease. The production of Beta lactamase enzymes (ESBL) in this bacterium makes it resistant to many antibiotics. The aim of this study was to evaluate a novel method single daily dose of Amikacin at 48 h intervals in a clinical trial This was a double-blind clinical trial study.Material and Methods: The patients were divided into two groups of Intervention (Administration of single daily dose of Amikacin at 48 h intervals Intervals for 1 week 3 doses) and control (Prescription of Meropenem for 1 Week). Results: The mean age of the Intervention group was (46.64±3.89) and control group (46.03±2.38). The frequency of E. coli infection was 61(54%), and that of other infections was 52(46%).Conclusion: The results of our study show the therapeutic effect of single daily dose administration of Amikacin every 48 hours

D-Propranolol Impairs EGFR Trafficking and Destabilizes Mutant p53 Counteracting AKT Signaling and Tumor Malignancy

Cancer therapy may be improved by the simultaneous interference of two or more oncogenic pathways contributing to tumor progression and aggressiveness, such as EGFR and p53. Tumor cells expressing gain-of-function (GOF) mutants of p53 (mutp53) are usually resistant to EGFR inhibitors and display invasive migration and AKT-mediated survival associated with enhanced EGFR recycling. D-Propranolol (D-Prop), the non-beta blocker enantiomer of propranolol, was previously shown to induce EGFR internalization through a PKA inhibitory pathway that blocks the recycling of the receptor. Here, we first show that D-Prop decreases the levels of EGFR at the surface of GOF mutp53 cells, relocating the receptor towards recycling endosomes, both in the absence of ligand and during stimulation with high concentrations of EGF or TGF-α. D-Prop also inactivates AKT signaling and reduces the invasive migration and viability of these mutp53 cells. Unexpectedly, mutp53 protein, which is stabilized by interaction with the chaperone HSP90 and mediates cell oncogenic addiction, becomes destabilized after D-Prop treatment. HSP90 phosphorylation by PKA and its interaction with mutp53 are decreased by D-Prop, releasing mutp53 towards proteasomal degradation. Furthermore, a single daily dose of D-Prop reproduces most of these effects in xenografts of aggressive gallbladder cancerous G-415 cells expressing GOF R282W mutp53, resulting in reduced tumor growth and extended mice survival. D-Prop then emerges as an old drug endowed with a novel therapeutic potential against EGFR- and mutp53-driven tumor traits that are common to a large variety of cancers.

P595 Finding predictors of azathioprine-induced pancreatitis in patients with inflammatory bowel disease

Background Azathioprine (AZA)-induced pancreatitis (AIP) is a common, idiosyncratic side effect, whose incidence, clinical course and risk factors data in inflammatory bowel disease (IBD) patients are scarce. We aimed to establish the incidence, describe the clinical course and identify risk factors for AIP. Methods Retrospective study including all IBD patients on AZA between January 2013 and July 2020. Patients with AIP were considered. Demographic, clinical, biochemical and imaging data were collected. Results AIP occurred in 33 patients (7.5%; 442 patients on AZA): 81.8% had Crohn’s disease, 54.5% were male, and the mean age was 35±13 years. The mean time under AZA till AIP was 25±11 days, with a mean dosage of 88±44mg. Eighteen patients (54.4%) were hospitalized, with a mean hospital stay of 4±2days. All patients had a mild course of disease which resolved with suspension of AZA, and with no complications or need of invasive interventions or complications. Smoking (p=0.02), single daily dose of AZA (p<0.001) and concomitant treatment with budesonide (p=0.001) were risk factors for AIP. In multivariate analysis, concomitant treatment with budesonide (OR: 5.3; p=0.002) and single daily dose of AZA (OR: 4.8; p=0.002) were the only predictors of AIP. Conclusion Although AIP was a relatively common side effect, it presented a mild course in all patients. Smoking, concomitant treatment with budesonide and single daily dose of AZA were risk factors for AIP. This study suggests that smoking, concomitant use of budesonide and single dose regimen of AZA should be avoided in IBD patients treated with AZA.

Low dose of Dasatinib in chronic myeloid leukemia

The oncoprotein BCR-ABL1 helps with the diagnosis and monitoring the therapeutic response in patients with chronic myeloid leukemia. We describe the case of a 70-year-old woman with chronic myeloid leukemia who did not achieve a molecular response after 12 months of treatment. She was then managed with Dasatinib 70 mg orally twice a day until she reached a complete molecular response. She developed pulmonary toxicity probably due to Dasatinib. The dosage was decreased to 70 mg orally once a day. The patient continues with a complete molecular response with less side effects. In chronic myeloid leukemia, as far as we know, there are no previous reports, after a molecular response with Dasatinib 70 mg twice a day, the maintenance of a good molecular control with a single daily dose. This dose may allow a reduction in toxicity with a better quality of life for patients with chronic myeloid leukemia

A Case Report of Sleep-Related Painful Erection Successfully Treated with Paroxetine

Sleep-Related Painful Erection (SRPE) is a rare condition characterized by recurrent, painful penile erections occurring when awakening from the Rapid Eye Movement (REM) sleep stage. The cause of SRPE is still unknown, the therapeutic strategies still in an expert-based opinion phase and there is no consensus yet. We present a case of a 23-year-old patient suffering from SRPE for 1 year, the smart bracelet which has a sleep monitoring function showed his sleep was fragmented by awakenings at the end of all the REM period. Several treatments such as tamsulosin and highfrequency hyperthermia therapy and Chinese herbal medicine did not prompt any improvement of his condition, but after taking a single daily dose of paroxetine 20mg for twelves weeks, both the frequency and intensity of SRPE gradually decreased. Even though the antidepressants to which paroxetine belongs were included as one of the abandoned treatments in recent review, in our case, paroxetine showed a long-term and stable effect on patients with SRPE, it indicates that the therapeutic effect of paroxetine on SRPE deserves further study and observation.

Effectiveness Oral Theophylline, Piracetam, and Iron Treatments in Children With Simple Breath-Holding Spells

Breath-holding spells (BHS) are common nonepileptic paroxysmal events in children. This is a retrospective study to compare the effectiveness of oral theophylline, piracetam, and iron treatments in children with simple BHS. A total of 146 children (75 girls and 71 boys) with simple BHS were included to this retrospective study. Children were divided into 4 groups: nontreated (no anemia and no treatment), oral theophylline (10 mg/kg/d as a single daily dose), piracetam (40 mg/kg/d in 2 divided doses), and elementary iron (3 mg/kg/d as a single daily dose) treatments. Iron therapy had been given only in children with iron deficiency anemia. Neurologic, cardiologic, and biochemical evaluations were performed for all children. The majority of the patients had cyanotic spells (83.6%). The frequency of attacks/month was markedly decreased with iron (58.8%) and theophylline (82.9%) treatments, but not with piracetam therapy (8.8%) and nontreated group (4.7%). Satisfaction of the parents/caregivers was found to be high in the theophylline group ( P < .001). Our results showed that theophylline was the most effective therapy to decrease the frequency of simple BHS in children.

Dietary Intake of Vitamin B12 is Better for Restoring a Low B12 Status Than a Daily High-Dose Vitamin Pill: An Experimental Study in Rats

Vitamin B12 (B12) is present in foods of animal origin, and vegans are encouraged to take supplements with synthetic B12 in order to ensure a sufficient uptake. Recent rat studies suggest that natural (hydroxo-B12, HO-B12) and synthetic (cyano-B12, CN-B12) B12 behave differently in the body. Here, we test if a daily vitamin pill matches dietary B12 in ability to restore a low B12 status in rats. B12-depleted male Wistar rats (n = 60) were divided into five groups (n = 12 in each) and subjected to two weeks intervention with various schemes of B12 supplementation. Two “dietary” groups received a low-B12 chow that was fortified with either HO-B12 or CN-B12 providing a continuous supply. Two “pill” groups received a single daily dose of CN-B12, where the vitamin content either matched or exceeded by factor four the provisions for the “dietary” groups. A control group received the low-B12 chow without B12 fortification. B12 was measured in plasma and tissues. Dietary B12 provides 35% more B12 to the tissues than an equivalent single daily dose (p < 0.0001). Natural B12 delivers 25% more B12 to the liver than synthetic B12 (p = 0.0007). A fourfold increase in B12, supplemented as a single daily dose, does not provide any extra B12 to the tissues (p = 0.45). We conclude that dietary B12 is better at rescuing a low B12 status than a daily vitamin pill.